Cappellini Maria D, Musallam Khaled M, Taher Ali T
Universitá di MilanoPoliclinico Foundation IRCCS, Milan, Italy.
Hemoglobin. 2009;33 Suppl 1:S58-69. doi: 10.3109/03630260903346924.
Chronic iron overload from frequent blood transfusions to treat patients with severe anemias leads to significant morbidity and mortality. Although desferrioxamine, the current standard of care, is an effective iron chelator with long-term evidence, it requires tedious subcutaneous infusion that reflects negatively on patient compliance. Deferiprone opened the horizon for an era of oral iron chelators. Although collective evidence proved its efficacy, safety issues are still of high concern and require regular monitoring. The experience with these two drugs helps better delineate the optimal goals of iron chelation therapy and the ideal iron chelator.
频繁输血治疗严重贫血导致的慢性铁过载会引发显著的发病率和死亡率。尽管目前的标准治疗药物去铁胺是一种有效的铁螯合剂且有长期证据支持，但它需要繁琐的皮下输注，这对患者的依从性有负面影响。去铁酮开启了口服铁螯合剂时代。尽管总体证据证明了其疗效，但安全问题仍备受关注，需要定期监测。这两种药物的使用经验有助于更好地明确铁螯合治疗的最佳目标和理想的铁螯合剂。
